Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Relapsed aggressive lymphomas are often treated with platinum-based chemotherapy (PBC) followed by an autologous stem cell transplant (ASCT). Response rates to PBC in patients with relapsed aggressive lymphomas are c. 60%, and non-responders have a dismal prognosis. Novel therapies for aggressive ly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Westin, Jason R., McLaughlin, Peter, Romaguera, Jorge, Hagemeister, Fredrick B., Pro, Barbara, Dang, Nam H., Samaniego, Felipe, Rodriguez, Maria A., Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle, Fowler, Nathan, Nastoupil, Loretta, Feng, Lei, Loyer, Evelyn, Younes, Anas
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5279071/
https://ncbi.nlm.nih.gov/pubmed/25039868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados